Invention Grant
- Patent Title: Piperazine derivatives as TRPML modulators
-
Application No.: US16311272Application Date: 2017-06-29
-
Publication No.: US10851084B2Publication Date: 2020-12-01
- Inventor: Congxin Liang
- Applicant: CalyGene Biotechnology, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Lysoway Therapeutics, Inc.
- Current Assignee: Lysoway Therapeutics, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Milstein Zhang & Wu LLC
- International Application: PCT/US2017/039848 WO 20170629
- International Announcement: WO2018/005713 WO 20180104
- Main IPC: C07D403/04
- IPC: C07D403/04 ; C07D401/04 ; C07D241/04 ; C07D295/096 ; C07D213/76 ; C07D295/135 ; C07D239/48 ; A61P21/00 ; A61P17/00 ; A61P25/16 ; A61P25/28
Abstract:
The new piperazine derivatives are modulators of TRPML and are useful in treating disorders related to TRPML activities such as lysosome storage diseases, muscular dystrophy, age-related common neurodegenerative diseases, oxidative stress or reactive oxygen species (ROS) related diseases, and ageing.
Public/Granted literature
- US20190248764A1 PIPERAZINE DERIVATIVES AS TRPML MODULATORS Public/Granted day:2019-08-15
Information query
